{"id":"NCT02363998","sponsor":"USWM, LLC (dba US WorldMeds)","briefTitle":"Open-Label, Safety Study of Lofexidine","officialTitle":"A Phase 3, Open-Label, Safety Study of Lofexidine","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-02","primaryCompletion":"2015-09","completion":"2015-10","firstPosted":"2015-02-16","resultsPosted":"2021-04-26","lastUpdate":"2022-03-22"},"enrollment":286,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Opioid Withdrawal"],"interventions":[{"type":"DRUG","name":"Lofexidine","otherNames":["Lofexidine hydrochloride (HCL)"]}],"arms":[{"label":"Open Label Lofexidine","type":"OTHER"}],"summary":"The purpose of this Phase 3 open-label treatment study is to evaluate the safety and effectiveness of lofexidine at a clinically relevant dose to alleviate symptoms of acute withdrawal from any opioid, including methadone and buprenorphine. This study will take place in a variety of clinical scenarios, both in-clinic and outpatient settings.","primaryOutcome":{"measure":"Overall Occurrence of Treatment Emergent Adverse Events (TEAEs)","timeFrame":"Days 1-14","effectByArm":[{"arm":"OL: Lofexidine HCl","deltaMin":270,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":7},"locations":{"siteCount":18,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":286},"commonTop":["Insomnia","Anxiety","Orthostatic hypotension","Hypotension","Bradycardia"]}}